RxDoctor Payments Data

Hal Chadow, MD

Cardiovascular Disease · Brooklyn, NYNPI 1669466835

Payments from drug & device makers

$50,163in general payments, 2019–2025

Across 588 payments — averaging $85.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$27K
  • Stryker$5K
  • Abbott$3K
  • Penumbra, Inc.$2K
  • Novartis$2K
  • Medtronic$1K
  • plus $11K from 52 others

What the payments were for

  • Consulting fees$14,32529%
  • Speaking & faculty fees$8,30017%
  • Travel & lodging$8,06316%
  • Food & beverage$19,35739%
  • Education$1180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,163 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$50,058
Medicare patients
774
Services billed
1,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan118$97,021
FarxigaDapagliflozin Propanediol117$94,907
BrilintaTicagrelor69$49,952
EliquisApixaban58$48,256
JardianceEmpagliflozin33$43,333
XareltoRivaroxaban35$29,283
JanuviaSitagliptin Phosphate20$12,926
Repatha SyringeEvolocumab12$9,602
Nifedipine ErNifedipine131$3,821
Atorvastatin Calcium269$3,300
Metoprolol Succinate126$1,872
Ezetimibe62$1,551
Losartan Potassium116$1,229
Chlorthalidone60$1,008
Spironolactone107$746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$610$144,859186 claims
NovartisEntresto$1,847$97,021118 claims
PfizerEliquis$485$48,25658 claims
Boehringer IngelheimJardiance$476$43,33333 claims
Johnson & JohnsonXarelto$715$29,28335 claims
MerckJanuvia$650$12,92620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →